Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma

Glioblastoma (GBM) is an aggressive primary brain tumor that is associated with a poor prognosis and quality of life. The standard of care has changed minimally over the past two decades and currently consists of surgery followed by radiotherapy (RT), concomitant and adjuvant temozolomide, and tumor...

Full description

Bibliographic Details
Main Authors: Jennifer K. Matsui, Haley K. Perlow, Alex R. Ritter, Rituraj Upadhyay, Raju R. Raval, Evan M. Thomas, Sasha J. Beyer, Clement Pillainayagam, Justin Goranovich, Shirley Ong, Pierre Giglio, Joshua D. Palmer
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
glioblastoma
radioresistance
radiosensitizer
glioma stem cell
tumor hypoxia
Online Access:https://www.mdpi.com/2227-9059/10/7/1763

Similar Items

Similar Items